Electromed, Inc. (ELMD) - 10-K Summary
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for Electromed, Inc. for the fiscal year ended June 30, 2026. Electromed develops, manufactures, and markets the SmartVest System, a High Frequency Chest Wall Oscillation (HFCWO) device used for airway clearance therapy in patients with compromised pulmonary function (e.g., bronchiectasis, cystic fibrosis). The company operates primarily through a direct-to-patient and provider model in the U.S. homecare market, disintermediating traditional distributors to capture manufacturer and distributor margins. It is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Fiscal 2026 | Fiscal 2025 |
|---|---|---|
| Net Revenues | $73,776,000 | $64,000,000 |
| Gross Profit | $57,943,000 | $49,971,000 |
| Gross Margin | 78.5% | 78.1% |
| Operating Income | $13,881,000 | $9,660,000 |
| Net Income | $11,301,000 | $7,537,000 |
| Diluted EPS | $1.30 | $0.85 |
| Cash from Operations | $9,665,000 | $11,393,000 |
| Cash and Equivalents (End of Period) | $20,450,000 | $15,287,000 |
| Working Capital | $45,146,000 | $34,614,000 |
| Debt (Revolving Credit Facility) | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased by 15.3% ($9.8 million) driven primarily by a 16.3% increase in homecare revenue. This growth was attributed to higher sales volume (driven by an increased sales force from 54 to 58 representatives) and higher net revenue per approval.
- Profitability: Operating income rose 43.7% to $13.9 million, and net income increased 49.9% to $11.3 million. The effective tax rate decreased from 26.7% to 21.3%, aided by R&D tax credits and the absence of non-deductible officer compensation seen in the prior year.
- Operating Expenses: SG&A expenses increased 8.7% due to higher payroll, travel, and marketing costs associated with sales force expansion. R&D expenses increased 31.9% due to higher headcount and consulting fees for product enhancements.
- Capital Allocation: The company repurchased 151,911 shares of common stock for approximately $3.9 million under a $10 million authorization. Capital expenditures increased significantly to $1.25 million (from $0.26 million) due to manufacturing and building improvement projects.
Guidance, Outlook, and Risks
Outlook and Strategy: Management plans to accelerate revenue growth in fiscal 2027 by expanding the sales force in high-potential geographies, increasing brand awareness, and developing clinical evidence for bronchiectasis treatment. The company expects to finance operations through cash flows and its existing credit facility.
Liquidity: The company maintains a $10 million revolving credit facility with BMO Bank N.A., maturing December 16, 2026. There was no outstanding balance as of June 30, 2026. Management believes working capital and available borrowings are sufficient for the next 12 months.
Risks and Contingencies:
- Regulatory and Legislative: Significant uncertainty exists regarding the "One Big Beautiful Bill Act" (OBBBA) signed in July 2025, which may reduce federal spending on Medicare/Medicaid and increase the uninsured population. Additionally, the Supreme Court's Loper Bright decision introduces uncertainty in federal regulatory interpretations.
- Reimbursement: Revenue is heavily dependent on third-party payer reimbursement (Medicare, Medicaid, private insurance). Changes in coverage policies or reimbursement rates could materially impact financial results.
- Supply Chain: Risks include component shortages, inflation in electronic components, and trade regulation changes (tariffs) which could increase costs and reduce gross margins.
Investor Verification Checklist
- Reimbursement Rates: Verify current Medicare and Medicaid allowable amounts for HCPCS code E0483 and monitor for potential reductions under new federal legislation (OBBBA).
- Sales Force Efficiency: Assess the return on investment for the expanded sales force (58 reps) and the sustainability of the 16.3% homecare revenue growth.
- Credit Facility Renewal: Confirm the status of the $10 million credit facility renewal prior to its December 2026 maturity.
- Accounts Receivable: Review the $5.1 million increase in accounts receivable and the adequacy of the allowance for credit losses given the reliance on third-party payers.
- Related Party Transactions: Note the $2.3 million in payments to a parts supplier owned by a former director and current 5% shareholder.